Stockscreener 앱 받기
3.20
0.95%
0.03
전일 마감가:
$3.17
열려 있는:
$3.21
하루 거래량:
7,899
Relative Volume:
0.48
시가총액:
$23.58M
수익:
$2.67M
순이익/손실:
$-54.17M
주가수익비율:
-8.651
EPS:
-0.3699
순현금흐름:
$-39.34M
1주 성능:
+0.00%
1개월 성능:
-39.87%
6개월 성능:
-71.97%
1년 성능:
-92.04%
1일 변동 폭
$3.10
$3.23
1주일 범위
$3.0727
$3.4195
52주 변동 폭
$3.06
$70.60
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
3.20 | 23.58M | 2.67M | -54.17M | -39.34M | -0.3699 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 다운그레이드 | Citizens | Mkt Outperform → Mkt Perform |
| 2026-03-13 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2026-03-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2026-02-17 | 개시 | Citizens | Mkt Outperform |
| 2024-05-17 | 개시 | CapitalOne | Overweight |
| 2023-08-03 | 개시 | Robert W. Baird | Outperform |
| 2021-08-03 | 개시 | Ladenburg Thalmann | Buy |
| 2021-07-16 | 재개 | Maxim Group | Buy |
| 2018-09-28 | 개시 | B. Riley FBR | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
모두보기
Immutep Limited Adr 주식(IMMP)의 최신 뉴스
After 10 business days at $1 or more, Immutep (Nasdaq: IMMP) gets Nasdaq’s bid-price decision. - Stock Titan
Nasdaq closed Immutep's listing case after 10 business days meeting the $1 bid minimum. - Stock Titan
Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change - The Globe and Mail
Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change - TipRanks
Immutep Regains Nasdaq Minimum Bid Price Compliance After ADS Ratio Change Effective 28 September 2026 - Kalkine
Immutep Achieves Nasdaq Minimum Bid Price Compliance Following ADS Ratio Adjustment Effective September 28, 2026 - Kalkine Media
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Immutep (NASDAQ: IMMP) Announces ADS Ratio Adjustment Effective September 28 to Meet Nasdaq Price Criteria - Kalkine Media
Immutep Resets ADS Ratio to Bolster Nasdaq Listing Compliance - TipRanks
Immutep (IMMP) plans 1-for-20 ADS reverse split to address Nasdaq bid-price deficiency - Stock Titan
Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares - marketscreener.com
Change to American Depositary Share Ratio - GlobeNewswire
A Nasdaq $1 price rule is behind Immutep’s planned 20-for-1 share swap - Stock Titan
Immutep Adjusts ADS Ratio to Safeguard Nasdaq Listing - TipRanks
Immutep (IMMP) retools lead cancer drug after trial halt, with next studies years away - Stock Titan
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneValue Area High - careplusvn.com
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneAAII Neutral - siam.in
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneMomentum Factor - dars.gov.et
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneRatio Spread Trade - dars.gov.et
Immutep (NASDAQ: IMMP) halts Phase III lung cancer trial and returns cash to Dr Reddy’s - Stock Titan
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesCapex Guidance - careplusvn.com
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesEPS Surprise History - dars.gov.et
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment Continues - dars.gov.et
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesLow Growth Earnings - dars.gov.et
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesEPS Guidance Update - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingSchiff Line - siam.in
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingMoney Flow Index - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingTrend Continuation Trade - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingHigh Dividend Factor - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingReversal Trade - www.dars.gov.et
Immutep (IMMP) Stock: Ends Down by 0.84% at $0.39 in Latest Trading; Immediate View: the Session Ends Within the Reported Technical Boundaries in the Available RecordLeading Diagonal - dars.gov.et
Immutep (IMMP) Trading: Finishes 1.01% Lower at $0.39 in Latest Trading; Next Session: the Current Price Sits Inside the Supplied Technical Range at the CloseIchimoku TK Cross - careplusvn.com
Immutep (IMMP) Trading: Finishes 1.01% Lower at $0.39 in Latest Trading; Next Session: the Current Price Sits Inside the Supplied Technical Range at the CloseRisk Reversal - dars.gov.et
Immutep (IMMP) Results Review: EPS Falls Short of Its Estimate at the Close; Investor Response: Shares Move Lower 1.01% in the Latest SessionGuidance Revision Trend - dars.gov.et
Immutep (IMMP) Trading: Finishes 1.01% Lower at $0.39 in Latest Trading; Next Session: the Current Price Sits Inside the Supplied Technical Range at the CloseOvervalued Signals - dars.gov.et
Immutep (IMMP) Results Review: EPS Falls Short of Its Estimate at the Close; Investor Response: Shares Move Lower 1.01% in the Latest SessionEarnings Growth Analysis - dars.gov.et
Immutep (IMMP) Results Review: EPS Falls Short of Its Estimate at the Close; Investor Response: Shares Move Lower 1.01% in the Latest SessionQuarterly Earnings - dars.gov.et
Immutep (IMMP) Holds Steady at $0.38 as Shares Test Key Support ZoneMcClellan Summation - careplusvn.com
IMMP Q2 2026 Earnings: Pre-Revenue Loss Misses by 9.89%, Yet Shares Gain 2.85%Quarterly Earnings - careplusvn.com
IMMP Q2 2026 Earnings: Wider-Than-Expected Loss, Yet ADS Advances 2.85%Balance Sheet Strength - dars.gov.et
Immutep Ltd Sponsored ADR Revenue Breakdown – FWB:YP1A - TradingView
Immutep Ltd Sponsored ADR Revenue Breakdown – MUN:YP1A - TradingView
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Immutep (IMMP) Retreats After Recent Gains, Testing Key Support at $0.39Low Beta Factor - careplusvn.com
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Immutep (ASX:IMM) Shares Surge Nearly 14% as Healthcare Momentum Grabs the ASX Spotlight - Kalkine
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Immutep Limited Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsIMMP - Finansavisen
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming DeadlinesIMMP - Finansavisen
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Immutep Limited Adr (IMMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.09%
0.72%
자본화:
|
볼륨(24시간):